Bupropion sustained release
and smoking cessation

Goldstein MG
Miriam Hospital and Department of
Psychiatry and Human Behavior,
Brown University School of Medicine,
Providence, RI 02906, USA.
J Clin Psychiatry 1998; 59 Suppl 4:66-72


The identification of nicotine dependence as a psychiatric disorder and increased knowledge of nicotine's neuropharmacologic effects have stimulated researchers to search for new pharmacologic interventions for smoking cessation. After reviewing the efficacy and safety of bupropion sustained release (SR) as an agent for treating smoking cessation, the Food and Drug Administration recently approved the use of bupropion SR for this indication. This paper reviews nicotine's pharmacologic effects and the factors contributing to the development of nicotine dependence, the general principles and strategies for treating nicotine dependence, and the evidence for the efficacy of bupropion SR as a treatment for smoking cessation. The release of bupropion SR as a treatment for smoking cessation may provide clinicians with additional opportunities to address smoking cessation with their patients.
Bupropion SR
Coffee and fags
Zyban: why worry?
Bupropion and mania
Smoking and depression
Antidepressants: nicotine
Bupropion and depression
Bupropion for nicotine quitters
Bupropion and nicotinic receptors
Can hypericum help tobacco addicts?
Bupropion, noradrenaline and serotonin
Bupropion, amphetamine and cigarettes
Quitting smoking: the role of antidepressants
Bupropion (Zyban): prescribing information (PDF)
Bupropion enhances pleasure for smokers who quit
Zyban/bupropion SR for tobacco smokers in remission

and further reading

Future Opioids
BLTC Research
Utopian Surgery?
The Abolitionist Project
The Hedonistic Imperative
The Reproductive Revolution
Critique of Huxley's Brave New World

The Good Drug Guide
The Good Drug Guide

The Responsible Parent's Guide
To Healthy Mood Boosters For All The Family